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improved survival (1.7% vs. 2.7%, P  0.001). In multi-
variate analysis, stent use was not associated with a sig-
nificantly lower risk of a revascularization procedure on
readmission to the same institution [OR 0.95, 95% CI
(0.87–1.04), P  0 .28]. From the health care system’s
perspective, 106 patients would need to be treated with a
stent to prevent one death on sentinel admission. CON-
CLUSION: Stent use decreased in-patient mortality by
1% without impacting length of stay or readmission
rates. At $149,354 per life year saved, stents would need
to increase a person’s life expectancy by a minimum of
three years over that which is gained from PTCA alone to
remain a cost-effective alternative.
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Data is available on stent PTCA restenosis rates in RCTs
but little data is available on restenosis rates and medical
costs in actual practice. OBJECTIVES: To compare rest-
enosis rates (repeat PTCA or stent, coronary artery by-
pass grafting, or myocardial infarction) and medical care
costs during one year post-PTCA for patients with and
without stents. METHODS: A total of 1756 patients
with index PTCA during 1995 and no PTCA in the prior
1 year were identified from a medical claims database of
large self-insured plans covering 1.7 million lives. Stents
were received by 373 of 1756 PTCA patients during the
index PTCA. RESULTS: Restenosis occurred in 316
(22.8%) of 1383 non-stent patients versus 62 (16.6%) of
373 (P  0.001) stent patients. For the one-year period
following index PTCA, ischemic heart disease (IHD)-
related medical costs were not significantly different be-
tween stent (mean  $5898,) and non-stent (Mean 
$7018) groups (P  0.18) nor did total medical costs dif-
fer among stent (Mean  $14,128) and non-stent (Mean 
$13,621) groups (P  0.71). Logistic regression (includ-
ing: age, gender, comorbidities, prior year hospitaliza-
tions, percent of IHD hospitalizations in prior year,
PTCA length of stay, and inpatient-PTCA) revealed
lower probability of restenosis (odds ratio  0.7, P 
0.02) in stent patients. Cost regressions using the same
covariates revealed no significant difference in IHD re-
lated costs or total medical costs for the one year period
following index PTCA. CONCLUSIONS: Although stented
patients had lower restenosis rates, 1-year medical costs
following PTCA were not significantly different based on
stenting.
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COST ANALYSIS OF INHALED AGENTS IN 
CANADIAN PEDIATRIC HOSPITALS
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Inhaled agents and propofol are used to sedate patients
for surgical interventions. Economic analysis of these
agents is complex and includes acquisition cost, wastage,
adjuvants, flow rate of fresh gas, equipments, and pa-
tient-specific factors. OBJECTIVES: The study purpose
was to benchmark annual costs of halothane, isoflurane,
desflurane, sevoflurane, enflurane, thiopenthal and pro-
pofol in Canadian pediatric institutions. METHODS: A
written survey was sent to 9 major hospital pharmacy de-
partments in 1999 with 2 recalls regarding the 1997–98
and 1998–99 fiscal years. RESULTS: Response rate was
78% (7/9). Our cohort includes a total 1005 beds,
48,659 admissions/year and 64,552 surgical procedures/
year. Day surgery represents 31% of total cases. Inhaled
agents and propofol represented 47.4% (n  7, sd  8.1)
of total drug costs in operating room (OR) and recovery
room (RR). Anesthetic agents costs were on average
$0.18 CAN/min of surgery (n  4, sd  0.05) in 1997–
98 and $0.21 CAN/min (n  3, sd  0.13) in 1998–99.
Total costs/patient of all drugs used were $430.26 CAN
(n  4, sd  8.8) in 1997–98 and $26.11 CAN (n  4,
sd  6.28) in 1998–99. Total costs/patient for anesthetic
agents were $13.54 CAN (n  4, sd  2.7) in 1997–98
and $12.48 CAN (n  4, sd  1.98) in 1998–99. Costs
reduction seems to be mainly caused by price reduction
of isoflurane for 1998–99 which went from 1st position
in 1997–98 ($171,610 CAN, n  5) to 3rd position in
1998–99 ($116,700 CAN, n  5) even with a 10% in-
crease in consumption. Total costs of these agents
increased by 3.5%. Sevoflurane has taken the 1st position
in 1998–99. CONCLUSION: There are little data avail-
able in the literature to allow benchmarking in the pedi-
atric OR. Further studies are required to identify the best
ratio useful to monitor such costs as well as relevant out-
comes.
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BACKGROUND: Treatment of intra-abdominal infec-
tions (IAI) has important health economic components
including hospital stay and the cost and administration of
pharmaceuticals. METHODS: From the hospital’s per-
spective, time-to-discharge (TTD) was evaluated for 258
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efficacy-evaluable (EE), IAI patients who received piper-
acillin/tazobactam (pip/tazo, 4g/500 mg) or imipenem/
cilastatin (imip/cil, 1g/1g) q8 hr by slow infusion in a
randomized, double blind study. Baseline severity was
evaluated using the APACHE II scoring system. Clinical
and bacteriological efficacy was similar across treatment
groups. A Cox proportional hazards analysis was used to
estimate TTD adjusting for APACHE II scores. RE-
SULTS: Baseline APACHE II scores were higher in the
pip/tazo group than the imip/cil group for the intent-to-
treat population (P  0.04) and EE population (P 
0.07). The pip/tazo group had a 23% lower instanta-
neous rate of hospital discharge (IRHD) compared to the
imip/cil group (relative odds  0.77; P  0.04). Severity
adjustment using the APACHE II indicated that treat-
ment-related differences in IRHD were not different (P 
0.12). APACHE II independently predicted TTD; a 1-point
increase in APACHE II score was associated with a 6%
lower IRHD (relative odds  0.94; P  0.001). Pip/tazo
patients were treated for IAI for an average of 7.6 days
compared to 7.1 days for imip/cil patients. Combining
daily average wholesale price (imip/cil $169.89 vs. pip/
tazo $64.26) and equivalent administration costs resulted
in a saving of $718 per course of therapy. CONCLU-
SIONS: Treatment with pip/tazo is equivalent to imip/cil
in terms of efficacy, duration of treatment and APACHE
II-adjusted hospital length-of-stay for IAI, but cost saving
due to lower acquisition costs.
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Advances in technology and surgical methods have al-
lowed an increasing number of surgical procedures to be
performed on an ambulatory basis, which has improved
patient outcomes and decreased the costs associated with
many of these procedures. Unfortunately, an area that
continues to exhibit negative clinical and economic con-
sequences is postoperative nausea and vomiting (PONV).
The prevalence of PONV after general anesthesia, even
for those surgeries performed on an ambulatory basis, re-
mains quite high and is a leading cause of delayed dis-
charge and unanticipated hospitalization in these pa-
tients. OBJECTIVE: To test the efficacy, safety, and
economic impact of an algorithm for PONV prophylaxis.
METHODS: From October to December 1999, baseline
data were collected on 473 consecutive patients undergo-
ing surgical procedures of any kind, including demo-
graphic data, risk factors for PONV, medication utiliza-
tion, occurrence of PONV, time in PACU, unanticipated
hospitalization, and patient satisfaction. Following im-
plementation of a PONV prophylaxis algorithm, data
will be collected for consecutive patients undergoing sur-
gical procedures and compared to the data from the base-
line period. RESULTS: Preliminary analysis of the base-
line data found that 34 of 473 patients (7.2%) had at
least one episode of emesis in the PACU. Thirteen of
these patients (38.2%) were delayed from being dis-
charged secondary to PONV; average time spent in the
PACU was 41 minutes for patients without PONV and
130 minutes for patients with PONV. Three patients
were hospitalized for PONV. CONCLUSION: Compari-
son of data before and after implementation of the dolas-
etron-based algorithm will allow us to determine the effi-
cacy, safety, and economic impact.
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Pharmacists have opportunities to provide cost savings in
an intensive care unit (ICU) by identifying potential
sources of errors. Due to the high intensity of drug costs,
a clinical pharmacist was placed in the ICU with the role
to evaluate drug utilization and identify potential oppor-
tunities to decrease costs while maintaining positive pa-
tient outcomes. OBJECTIVE: This pilot project evaluates
a pharmacist intervention program targeting antibiotic
cost reduction in a community hospital ICU. METH-
ODS: Pharmacist interventions include, but are not lim-
ited to, antibiotic streamlining, intravenous to oral switch,
total parenteral nutrition consults, pharmacokinetic con-
sults, dosage adjustments, identification of drug interac-
tions, and eliminating therapy duplications. Drug utilization
and drug cost for the ICU and the entire hospital (exclud-
ing the ICU and nursery), were calculated monthly and
included the total number of units dispensed, total drug
cost, drug cost per patient day, and units dispensed per
patient day. Outcomes for monitored antibiotics were
compared between the hospital and the ICU, as well as
before and after the clinical pharmacist intervention pro-
gram was initiated. RESULTS: Data is presented from
July 1999 to November 1999, with initiation of the inter-
vention being performed from August 1999. The average
antibiotic cost per ICU patient day was higher, $36.43,
as compared to overall hospital antibiotic cost per patient
day of $20.80. Mean antibiotic costs for the ICU decreased
significantly following the interventions and were as fol-
lows: July: $42.27; August, $36.99; September, $39.92;
October, $37.69; and November, $37.59. Average monthly
antibiotic units dispensed for the hospital were 5077
(1.59 units/patient day) and for the ICU were 817 (2.66
units/ICU patient day). The total number of pharmacist
interventions averaged 49 per month. No adverse patient
outcomes were reported during this period. CONCLU-
SION: We continue to monitor the effectiveness of a clin-
ical pharmacist in the ICU by monitoring drug utiliza-
